Bill Meury

Mr. Meury is Crown Chairman & Senior Operating Adviser at Hildred.  He is currently President and CEO at Karuna Therapeutics, a public neurology-focused biopharmaceutical company, and previously served as the Chief Commercial Officer for Allergan from 2015-2020 where he had total P&L responsibility for over 50 products with $16 billion in revenue and over $3 billion in sales and marketing investment.  He led multiple divisions consisting of 8,000 people around the world, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Previously, Mr. Meury served as President, Branded Pharmaceuticals for Actavis, and Executive Vice President, Sales and Marketing, Forest Laboratories, Inc.  

Mr. Meury led three large commercial integrations, including the $28 billion merger between Forest & Actavis, the $66 billion merger between Actavis & Allergan, and the $63 billion merger between Allergan & Abbvie.  He has over 25 years of experience in biopharmaceuticals and was directly responsible for over 20 new product launches across 10 therapeutic areas during his career.

Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications.

Mr. Meury serves on the Board of Directors for Syndax, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.  He also serves on the Board of Directors for the Jed Foundation, a non-profit organization that protects emotional health and prevents suicide for teens and young adults in the United States.

Mr. Meury has a B.A. in Economics from the University of Maryland.